AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05688202 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sequential combination of fractional CO2 laser and subcision
Description: Fractional CO2 laser conducted two weeks after subcision. Subcision is operated in all participants using an 181/2G Nokor needle (BD Nokor™ Admix Needles, United States). The insertion depth is at the dermal-hypodermal junction. The subcision needle is advanced and retracted in a tunneling motion to penetrate the fibrotic scar tissue, then slid in a direction parallel to the skin's surface in order to detach the scar from its tethers.~All participants undergo FrCO2 laser (10 600-nm eCO2 laser, Lutronic Corporation, Goyang, Korea) with the parameters following the suggested regimen at static mode: 120 μm beam size, 30 W peak power, 30 - 120 mJ pulse energy, 50-75 spots/cm2 density, with two passes: (1)Only the atrophic scars are treated using a 4mm square or circle pattern, 100-120 mJ pulse energy, and 50 spots/cm2 density. (2)The whole half side of the face is treated using a 12mm square pattern, 30-40 mJ pulse energy, and 75 spots/cm2 density, \<10% overlap.
Study NCT05688202 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional CO2 laser
Description: Fractional CO2 laser (10 600-nm eCO2 laser, Lutronic Corporation, Goyang, Korea) on both sides of the face sequentially with a two-week interval between sessions for each face's side by a single physician, with the parameters following the suggested regimen at static mode: 120 μm beam size, 30 W peak power, 30 - 120 mJ pulse energy, 50-75 spots/cm2 density, with two passes. At the first pass, only the atrophic scars are treated using a 4mm square or circle pattern, 100-120 mJ pulse energy, and 50 spots/cm2 density in the static operating mode. At the second pass, the whole half side of the face is treated using a 12mm square pattern, 30-40 mJ pulse energy, and 75 spots/cm2 density in the static operating mode with less than 10% overlap.
Study NCT05688202 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fractional CO2 laser
Description: Fractional CO2 laser (10 600-nm eCO2 laser, Lutronic Corporation, Goyang, Korea) on both sides of the face sequentially with a two-week interval between sessions for each face's side by a single physician, with the parameters following the suggested regimen at static mode: 120 μm beam size, 30 W peak power, 30 - 120 mJ pulse energy, 50-75 spots/cm2 density, with two passes. At the first pass, only the atrophic scars are treated using a 4mm square or circle pattern, 100-120 mJ pulse energy, and 50 spots/cm2 density in the static operating mode. At the second pass, the whole half side of the face is treated using a 12mm square pattern, 30-40 mJ pulse energy, and 75 spots/cm2 density in the static operating mode with less than 10% overlap.
Study NCT05688202 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcision
Description: Subcision is operated in all participants using an 1812G Nokor needle (BD Nokor™ Admix Needles, Becton, Dickinson and Company, New Jersey, United States). The operation sites are sterilized with alcohol pads and injected intradermally with a solution of 2% lidocaine. After obtaining appropriate anesthesia, a Nokor needle is inserted into the skin close to the depressed scars and progressed until it lays precisely under the scar. The insertion depth is at the dermal-hypodermal junction. Initially, the subcision needle is advanced and retracted in a tunneling motion to penetrate the fibrotic scar tissue. Once the fibrous mass has been sufficiently fractured, the needle is slid in a direction parallel to the skin's surface in order to detach the scar from its tethers. For densely fibrous scars, several needle insertion sites are used to undermine the defect from various angles.
Study NCT05688202 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Subcision
Description: Subcision is operated in all participants using an 1812G Nokor needle (BD Nokor™ Admix Needles, Becton, Dickinson and Company, New Jersey, United States). The operation sites are sterilized with alcohol pads and injected intradermally with a solution of 2% lidocaine. After obtaining appropriate anesthesia, a Nokor needle is inserted into the skin close to the depressed scars and progressed until it lays precisely under the scar. The insertion depth is at the dermal-hypodermal junction. Initially, the subcision needle is advanced and retracted in a tunneling motion to penetrate the fibrotic scar tissue. Once the fibrous mass has been sufficiently fractured, the needle is slid in a direction parallel to the skin's surface in order to detach the scar from its tethers. For densely fibrous scars, several needle insertion sites are used to undermine the defect from various angles.
Study NCT05688202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine/Prilocaine 2.5%-2.5% Topical Application Cream
Description: Preoperative, lidocaine 2.5% and prilocaine 2.5% cream (EMLA 5%, eutectic mixture of local anesthetic; AstraZeneca LP, Wilmington, DE, USA) is applied under occlusion for 60 minutes prior to the removal of local anesthetics
Study NCT05688202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine/Prilocaine 2.5%-2.5% Topical Application Cream
Description: Preoperative, lidocaine 2.5% and prilocaine 2.5% cream (EMLA 5%, eutectic mixture of local anesthetic; AstraZeneca LP, Wilmington, DE, USA) is applied under occlusion for 60 minutes prior to the removal of local anesthetics
Study NCT05688202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: A 500 mg paracetamol-based oral analgesic (Efferalgan, Upsa SAS, France) is administered right before the procedure.
Study NCT05688202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paracetamol
Description: A 500 mg paracetamol-based oral analgesic (Efferalgan, Upsa SAS, France) is administered right before the procedure.
Study NCT05688202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2% Injectable Solution
Description: The operation sites are sterilized with alcohol pads and injected intradermally with a solution of 2% lidocaine.
Study NCT05688202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine 2% Injectable Solution
Description: The operation sites are sterilized with alcohol pads and injected intradermally with a solution of 2% lidocaine.
Study NCT05068791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 0.36 mg/kg will be administered orally to participants
Study NCT05068791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextromethorphan
Description: 2.6 mg/kg of active placebo will be administered orally to participants
Study NCT04696289 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Standardized catheterization assessment
Description: There are four components to the pulmonary vein assessment.~1. Angiography: pulmonary artery wedge injection and/or selective pulmonary vein injection.~2. Intravascular ultrasound: manual pullback of IVUS catheter from lobar segment to left atrium.~3. Pressure assessment: pulmonary vein pressure (mmHg) measured before and after (if applicable) intervention.~4. Compliance testing: the compliance of the vein will be measured using a compliant conventional balloon.
Study NCT06288230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vesemnogene lantuparvovec
Description: Exploratory study evaluating the safety and efficacy of vesemnogene lantuparvovec in patients with SMA.
Study NCT01937663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KWA-0711
Study NCT04999384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AN4005-dose level 0
Description: 50mg BID
Study NCT04999384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AN4005-dose level 1
Description: 100mg BID
Study NCT04999384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AN4005-dose level 2
Description: 200mg BID
Study NCT05825365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selumetinib
Description: Selumetinib
Study NCT05825365 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Transfer to selumetinib on REiNS-defined PD)
Study NCT05687292 — intervention group
Intervention type: DEVICE
Intervention: Clinical decision support system (CDSS) for ventilator weaning
Description: A clinical decision support system (CDSS) will be integrated into a software program (the T3 platform) that is present on all patient bedside computers. The T3 platform is a tool that compiles data from a patient's existing physiologic monitors, ventilator, and laboratory results and graphically displays them on a bedside monitor. The CDSS will be active on all patients receiving mechanical ventilation, but primary use and evaluation will focus on patients meeting study criteria. Twice daily (on morning rounds and evening rounds), patients will be screened for eligibility. During each rounds, teams will review the CDSS and associated risk analytics data used to inform the associated recommendations for ventilator weaning, extubation readiness assessment, and extubation. The clinical team will consider the CDSS in decision making around ventilator weans. If the decision is made not to follow the CDSS recommendations, the clinician will complete a brief survey with rationale.
Study NCT05598957 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamin D Binding protein
Description: Vitamin D-free and bioavailable metabolites were calculated by using Bikle and Vermeulen methods with using albumin, 25-OH vitamin D, vitamin D binding protein (ELİSA kit) levels
Study NCT05900895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Participants will be treated with olaparib at the approved doses for the treatment of subtypes of breast cancer or at reduced dose/frequency for participants with moderate renal impairment.
Study NCT05900895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17b-estradiol
Description: 17b-estradiol will be taken orally three times per day.
Study NCT05624892 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mirror Therapy with Virtual Reality Application
Description: Researchers will apply Mirror Therapy with Virtual Reality Application to increase individuals' quality of life and motor sense gains.
Study NCT06147544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB-718
Description: Administered subcutaneously once a week
Study NCT06147544 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously once a week
Study NCT04999384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AN4005-dose level 3
Description: 400mg BID
Study NCT04999384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AN4005-dose level 4
Description: 600mg BID
Study NCT04999384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AN4005-food effect
Description: Dose to be determined upon the MTD determination
Study NCT04683146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hand antisepsis with Propanolol- 1 60%.
Description: * Pre-washing for one minute with neutral soap to remove the transient flora.~* Hand antisepsis using Propanolol-1 60% in both hands.~* Bacterial sample collection from right hand.~* Sterile surgical glove in both hands.~* Bacterial sample collection from left hand three hours later
Study NCT04799431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoantigen Vaccine with Poly-ICLC adjuvant
Description: Neoantigen Vaccine with Poly-ICLC adjuvant will be administered on days 1, 8, 15 and 22. 2 to 5 subcutaneous injections will be administered in the upper thighs, arms and/or back.~Drug: 0.3 mg per peptide vaccine + 0.5mg Poly-ICLC
Study NCT04799431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: 500 mg will be administered as a 30 minute IV. Infusion (-5 min/+15min) on Day 1 of each 28 day cycle every 4 weeks.
Study NCT04605484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Posoleucel (formerly known as ALVR105) cells
Description: Infusion
Study NCT04605484 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (visually identical to Posoleucel)
Description: Infusion
Study NCT04605484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (visually identical to Posoleucel)
Description: Infusion
Study NCT06406283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Functional Training (HIFT)
Description: This intervention will include three sessions per week: two group 60-minute zoom online synchronous sessions guided by experts and one individual autonomous session (a repetition of a chosen session of that week).~The training protocol will be designed based on Cross-Training workouts, emphasizing high-intensity interval training combined with functional resistance-training movements.
Study NCT06406283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction Program (MBSR)
Description: This intervention follows the official MBSR program designed by Jon Kabat-Zinn with some adaptations, as we did in Bermudo-Gallaguet, et al. (2022). The intervention will occur three days a week, including one 120-minute online synchronous session and two 20-40 min individual practices. The intensity of physical exercise will be adjusted to personal baseline characteristics.
Study NCT06406283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong
Description: This intervention will include three sessions per week: two group 60-minute zoom online synchronous sessions guided by experts and one individual autonomous session (a repetition of a chosen session of that week).~The program includes the Baduanjin sequence, considered one of the most ancient and beneficial forms for physical and mental health within the Qigong tradition.
Study NCT06093698 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Anti-EpCAM-CD3 Antibody Injection
Description: Intravenous Infusion
Study NCT04694417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression stocking
Description: Please see the description of the intervention in another section
Study NCT04694417 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium tablet
Description: Please see the description of the intervention in another section
Study NCT04694417 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Please see the description of the intervention in another section
Study NCT05168527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib,Albumin Paclitaxel,Gemcitabine
Description: The study will mainly explore the safety and tolerability of fixed-dose level of Fruquintinib (4 mg, continuous medication for 3 weeks and withdrawal for 1 week) combined with fixed-dose level of albumin paclitaxel and gemcitabine. The fixed dose of Fruquintinib is 4 mg, with a treatment cycle every 28 days. A 28-day observation window was used to explore the side effects of fruquintinib in the combined treatment of pancreatic cancer patients with liver metastases. Evaluable patients will be assessed for DLT within 28 days after the first administration of the study drug. The 24 patients enrolled in the follow-up group will mainly evaluate the initial efficacy of furquintinib combined with albumin paclitaxel and gemcitabine as the first-line standard treatment for patients with metastatic pancreatic cancer.
Study NCT06313814 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Swanson ginger capsule
Description: Swanson Ginger Root? gingerols, shogaols, and paradols, and possesses multiple bioactivities, such as antioxidant, anti-inflammatory, and antimicrobial properties.~Ginger is most commonly associated as a culinary spice flavouring to oriental dishes and even the local bakery character biscuit, the gingerbread man. But since ancient times the spice has also been recognized for its health properties, most popular being to settle the stomach, alleviate indigestion and event prevent motion sickness. More recently research has confirmed Ginger's historical effectiveness on digestive health and beyond.
Study NCT06373991 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATHENA CAR-T
Description: Phase 1 dose escalation (3+3): dose 1 and dose 2.
Study NCT06373991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Intravenous injection of fludarabine.
Study NCT06373991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous injection of cyclophosphamide.
Study NCT05949463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent teaching unit
Description: The intermittent group students performed an intermittent teaching unit twice a week for eight weeks aimed at promoting healthy physical activity habits. Specifically, the last 15 minutes of each lesson were used. The rest of lessons' time other contents were worked on with no relation to any health physical activity habit (i.e., acrosport, badminton, basketball, volleyball, soccer and athletics).
Study NCT05949463 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention group
Description: The control group students also carried out two Physical Education lessons a week during the intervention period. During these lessons, contents of handball, basketball, alternative sports and traditional games were developed. However, this group did not wear physical activity activity wristbands or receive any behavior modification specific strategy.
Study NCT06232473 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: Please see arm desciption
Study NCT05477810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (investigational drug) followed by Treatment B (reference drug)
Description: Two drug administration periods (1 and 2), each consisting of administration of Treatment A (investigational drug) followed by Treatment B (reference drug) on Day 1 will be performed. Post administration of the study drug standard PK sampling, measurement of vital signs, adverse events, ECG and VAS as per schedule will be done over a time period of 11 hours. The study participants will thereafter be discharged. The participants will return to the study center at 24, 48, 72 and 96 hours after study drug administration in each treatment period for blood sampling, vital signs and safety assessments as per schedule. The wash-out period between doses will be at least 7 days.
Study NCT05477810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment A (investigational drug) followed by Treatment B (reference drug)
Description: Two drug administration periods (1 and 2), each consisting of administration of Treatment A (investigational drug) followed by Treatment B (reference drug) on Day 1 will be performed. Post administration of the study drug standard PK sampling, measurement of vital signs, adverse events, ECG and VAS as per schedule will be done over a time period of 11 hours. The study participants will thereafter be discharged. The participants will return to the study center at 24, 48, 72 and 96 hours after study drug administration in each treatment period for blood sampling, vital signs and safety assessments as per schedule. The wash-out period between doses will be at least 7 days.
Study NCT05477810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B (reference drug) followed by Treatment A (investigational drug)
Description: Two drug administration periods (1 and 2), each consisting of administration of Treatment B (reference drug) followed by Treatment A (investigational drug) or on Day 1 will be performed. Post administration of the study drug standard PK sampling, measurement of vital signs, adverse events, ECG and VAS as per schedule will be done over a time period of 11 hours. The study participants will thereafter be discharged. The participants will return to the study center at 24, 48, 72 and 96 hours after study drug administration in each treatment period for blood sampling, vital signs and safety assessments as per schedule. The wash-out period between doses will be at least 7 days.
Study NCT05477810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment B (reference drug) followed by Treatment A (investigational drug)
Description: Two drug administration periods (1 and 2), each consisting of administration of Treatment B (reference drug) followed by Treatment A (investigational drug) or on Day 1 will be performed. Post administration of the study drug standard PK sampling, measurement of vital signs, adverse events, ECG and VAS as per schedule will be done over a time period of 11 hours. The study participants will thereafter be discharged. The participants will return to the study center at 24, 48, 72 and 96 hours after study drug administration in each treatment period for blood sampling, vital signs and safety assessments as per schedule. The wash-out period between doses will be at least 7 days.
Study NCT04683146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hand antisepsis with a solution of alcohol, chlorhexidine digluconate and potassium sorbate.
Description: * Pre-washing for one minute with neutral soap to remove the transient flora.~* Hand antisepsis using a solution of alcohol, chlorhexidine digluconate and potassium sorbate.~* Bacterial sample collection from right hand.~* Sterile surgical glove in both hands.~* Bacterial sample collection from left hand three hours later.
Study NCT06232473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Please see arm description
Study NCT06232473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benztropine Mesylate 0.5 MG and passive placebo RAP
Description: Please see arm description
Study NCT06232473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Benztropine Mesylate 0.5 MG and passive placebo RAP
Description: Please see arm description
Study NCT06232473 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced usual care
Description: Please see arm description
Study NCT06232473 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: Please see arm description